Jeffrey L. Kopacz is senior director of IP at Alnylam Pharmaceuticals in Cambridge, Massachusetts. He is responsible for IP matters related to Alnylam’s clinical and pre-clinical therapeutics, including securing and defending world-wide patent protection, plus due diligence of new technologies, licensing, and competitive and freedom-to-operate analysis. Prior to joining Alnylam Kopacz was an associate at Edwards, Angell Palmer & Dodge (now Locke Lord) and a patent agent at Millennium Pharmaceuticals. He received his JD from the Suffolk University Law School and his graduate degree in molecular microbiology and immunology from Johns Hopkins University.